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Background: Single circulating tumor cells (CTCs) or circulating tumor microemboli (CTMs) are potential biomarkers
of renal cell cancer (RCC), however studies of CTCs/CTMs in RCC are limited. In this pilot study we aimed to
evaluate a novel blood filtration technique suited for cytomorphological classification, immunocytochemical and
molecular characterization of filtered, so called circulating non-hematologic cells (CNHCs) - putative CTCs/CTMs - in
patients with RCC.
Methods: Blood of 40 patients with renal tumors was subjected to ScreenCell® filtration. CNHCs were classified
according to cytomorphological criteria. Immunocytochemical analysis was performed with antibodies against
CD45, CD31 and carbonic anhydrase IX (CAIX, a RCC marker). DNA of selected CNHCs and respective primary
tumors was analysed by array-CGH.
Results: CNHC-clusters with malignant or uncertain malignant cytomorphological features - putative CTMs - were
negative for CD45, positive for CD31, while only 6% were CAIX positive. Array-CGH revealed that 83% of malignant
and uncertain malignant cells did represent with a balanced genome whereas 17% presented genomic DNA
imbalances which did not match the aberrations of the primary tumors. Putative single CTCs were negative for
CD45, 33% were positive for CD31 and 56% were positive for CAIX.
Conclusions: The majority of CNHC-clusters, putative CTMs, retrieved by ScreenCell® filtration may be of endothelial
origin. Morphological criteria seem to be insufficient to distinguish malignant from non-malignant cells in renal
cancer.
Keywords: Circulating tumor cells, Circulating tumor microemboli, Renal cancer, ScreenCell®, Array comparative
genomic hybridization (array-CGH), Circulating endothelial cellsBackground
Hematogenous dissemination of single tumor cells (circu-
lating tumor cells, CTCs) or tumor microemboli (circulat-
ing tumor microemboli, CTM) is an important mechanism
involved in the formation of metastases, the major cause of
cancer related death [1]. Results of numerous studies* Correspondence: karoline.lackner@medunigraz.at
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reproduction in any medium, provided the orindicate the prognostic value of CTC detection and
enumeration in many human cancers. This has been
confirmed in recent meta analyses for breast [2] and
colorectal cancer [3]. Besides enumeration, results of
the molecular analyses of CTCs may be used to predict
treatment response [4]. Investigation of CTCs may
hold great promise to inform individualized treatment
strategies as well as to increase the knowledge about the
metastatic process in itself. Renal cell cancer (RCC) is the
most frequent solid lesion of the kidney and accounts for
3% of all cancer cases worldwide. Approximately 20% of
primary localized RCC will develop metastatic diseaseal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical and histopathological characteristics of
the study cohort
Parameter Patients, n; (%)
Age, median; (range) 68; (30–83)
Men 28; (70)
Women 12; (30)
Benign tumors 10; (25)
Renal cysts 1; (2.5)
Angiomyolipoma 2; (5)
Oncocytoma 6; (15)
Cystic Nephroma 1; (2.5)
Tumor size (cm), median; (range) 2.5; (1.0-6.0)
Malignant tumors 30; (75)
Clear cell RCC 25; (62.5)
Papillary RCC 5; (12.5)
Tumor size (cm), median; (range) 4; (1.3-12.0)
Tumor differentiation
G1 6; (20)
G2 16; (53.3)
G3 8; (26.7)
Venous invasion (in cases of
potentially invasive tumors)
6; (16)
Distant metastasis (in cases of
potentially invasive tumors)
1; (3)
Type of surgical intervention
Open partial nephrectomy 24; (60)
Open nephrectomy 6; (15)
Transperitoneal nephrectomy 4; (10)
Laparoscopic nephrectomy 3; (7.5)
Laparoscopic partial nephrectomy 2; (5)
CT targeted biopsy 1; (2.5)
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options are limited by resistance of RCC to chemotherapy
and radiation, but have recently been improved by the ad-
vent of targeted therapies [6,7]. As in other malignancies,
CTCs may also be valuable prognostic and predictive bio-
markers of renal cancers, however studies of CTCs in
RCC are limited (reviewed in [8]).
Several techniques for the detection and enumeration
of CTCs have been developed during the last years and
the list is continuously growing. Many methods use epithe-
lial antigenic properties of cancer cells to detect and isolate
them from blood by immunomagnetic or microfluidic
based enrichment methods (reviewed in [9]). However,
many of these detection systems are not commercially
available and/or economically accessible. Another obstacle
is the epithelial antigen-based detection of CTCs. Epithelial
to mesenchymal transition (EMT) is believed to represent
an integral component of the metastatic process in which
cancer cells down regulate the expression of epithelial
markers in favour of mesenchymal markers, a process
linked to the stemness of cancer cells and increased
chemoresistance [10-13]. Hence such CTCs may therefore
escape detection. Recently filtration based size exclusion
technologies have been developed [14,15] which allow for
antigen-independent isolation of CTCs from blood based
on their larger size and cytomorphological features in com-
parison to hematological cells [16]. Some of these methods
like the ScreenCell® filtration system are commercially
available. CTCs can be isolated from diluted blood in a sin-
gle step using a translucent polycarbonate membrane. Fol-
lowing filtration they can be further analysed by light
microscopy and immunocytochemistry [16-21] but mo-
lecular data on putative CTCs/CTMs are limited [21-23].
Using the ScreenCell® filtration system and array-CGH
technology we aimed to evaluate if morphological cri-
teria [17] are sufficient to identify CTCs/CTMs in blood
of renal cancer patients. Here we report for the first time
chromosomal analysis of circulating non-hematological
cell clusters cytomorphologically resembling CTMs by
array-CGH.
Methods
Ethical statement
The study was approved by the ethics committee of the
Medical University of Graz (reference EK: 19–239 ex 07/08).
Written informed consent was obtained from all patients.
The human iliac arterial endothelial primary cells (HIAEC)
(generously provided by Dr. I. Lang-Olip, Medical University
of Graz, Austria) derived from an organ donor. Ethical ap-
proval was granted by the ethics committee of the Medical
University of Graz (reference EK: 19–293 ex 07/08). The
ethics committee waived the need for written informed con-
sent as the donor fulfilled presumed-consent according to
Austrian Hospitals Act.Patients and tissues
Thirty consecutive patients diagnosed of renal cell carcin-
omas (25 clear cell and 5 papillary carcinomas) and for
control purposes 10 patients with benign renal tumors
(1 renal cyst, 2 angiomyolipoma, 6 oncocytoma and 1
cystic nephroma) diagnosed between 2010 and 2011
were included in the study. All patients underwent sur-
gical resection of the tumor. Clinical and histopatho-
logical parameters of the study cohort are compiled in
Table 1. Blood samples from 20 healthy volunteers
were used as age and sex matched negative controls.
Formaldehyde (4% m/V buffered solution)-fixed and
paraffin-embedded (FFPE) tumor specimens were re-
trieved from the BioBank of the Medical University of
Graz, Austria. In 40% of the cases tumor tissue snap
frozen in liquid nitrogen was available. All cancer pa-
tients were classified according to the TNM Classifica-
tion of Malignant Tumors of the International Union
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mors were staged T1a, five (17%) were classified as
T1b, four (13%) as T2a and four (13%) as T3a, respect-
ively. Six (20%) of RCC tumors were graded G1, 16
(53%) G2 and 8 (27%) G3, respectively. In the tumors
of six patients (16%) venous invasion was found.
Blood sample collection
From each patient a total of 4 blood samples were collected
in 2 × 6 ml EDTA tubes (Greiner Bio-One, Kremsmünster,
Austria) from a peripheral vein. The first sample was drawn
one day prior to surgery (time point A), the next time
points of collection were once, during surgery shortly after
removal of the tumor (time point B), one day after surgery
(time point C) and eight days after surgery (time point D).
DNA extraction of primary tumor tissue
Genomic DNA was extracted from snap frozen tumor tis-
sue or if not available, from FFPE tumor tissue using the
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) as de-
scribed by the manufacturer. DNA quantity and quality
was assessed by Nanodrop measurement (Thermo Fisher
Scientific, Waltham, USA) and DNA fragmentation was
analysed by agarose gel electrophoresis [25].
Cell lines and evaluation of the sensitivity of the
ScreenCell® filtration device
The female renal cell adenocarcinoma cell line 769-P was
purchased from ATCC (Manassas, USA) and cultivated in
RPMI supplemented with 10% fetal calf serum, 1 mM so-
dium pyruvate, 100U/ml penicillin and 100 μg/ml strepto-
mycin (all cell culture supplies from Gibco, Invitrogen,
Carlsbad, USA). The human iliac arterial endothelial
primary cells (HIAEC) (generously provided by Dr. I.
Lang-Olip, Medical University of Graz, Austria) were
grown in endothelial growth medium-2 (EGM-2) (Lonza,
Walkersville, USA).
The sensitivity of the ScreenCell® filtration method
was evaluated in nine independent experiments by spiking
cultured renal cell cancer cells (769-P cell line) into blood
samples from a healthy volunteer. Confluent 769-P cells
were harvested by trypsinization using 0.05% Trypsin-
EDTA buffer (PAA, Pasching, Austria). Then defined
numbers (three batches of 2, 10 and 50 individual
cells) were picked under an inverted microscope (Zeiss
Axiovert M 200, Munich, Germany) using a microma-
nipulator (MMJ, Zeiss; CellTram vario, Eppendorf,
Hamburg, Germany) equipped with microcapillaries
(inner diameter of 20 μm) (TransferTip, Eppendorf ).
Picked cells were directly transferred into the blood
sample which was then processed by filtration and
hematoxylin staining. Cells were enumerated and re-
covery rates were calculated.ScreenCell® filtration
All blood samples were processed within 4 hours after
collection of blood as recommended by the manufac-
turer (ScreenCell®, Paris, France). Filtration was carried
out as previously described [15] with minor modifica-
tions. Briefly, blood was diluted 8 fold with red blood
cell lysis buffer (ScreenCell®, Paris, France) and incu-
bated for 10 min at RT, with gentle agitation after 3 and
6 min. Per patient and time point 4 filtrations, each cor-
responding to the processing of 2 ml of whole blood
were performed using vacutainer tubes as described by
the manufacturer. Thereafter the filters were rinsed
with 2 ml of sterile phosphate-buffered saline (PBS
pH 7.4) and collected from the device. The filters were
counterstained with hematoxylin (Merck, Darmstadt,
Germany) for 5 min and blued for a few seconds with
NH3-H2O (0.06% m/V), washed in distilled water, air
dried and mounted on a glass slide for evaluation by
light microscopy. Of 14 selected cases (11 patients
with RCC, 1 with oncocytoma, and 2 cases with benign
tumors) three of the four filters remained unstained
and were stored at −20°C until further immunocyto-
chemical analysis.
Cytomorphological analyses of filtered cells
Stained filters were analysed by light microscopy by a board
certified cytopathologist (CL) using the cytomorphological
criteria recently issued by a panel of ten expert
cytopathologists for the classification of circulating non-
hematological cells (CNHC) filtered from blood using the
method “isolation by size of epithelial tumor cells” (ISET)
as published by Hofman et al. [17]. This filtration technol-
ogy is based on comparable principles for isolation of
CTCs/CTMs from blood, i.e. size exclusion by filtration
through a translucent polycarbonate membrane filter with
8 μm pore size using vacuum suction, as the ScreenCell®
system. Therefore cytomorphological criteria established
with ISET filtration may also be used to evaluate filtered
cells on ScreenCell® filters. The proposed criteria by
Hofman have also been applied to renal cell carcinoma
in one study [17]. According to these criteria filtered
cells >8 μm are classified as CNHC with malignant
(CNHC-MF), uncertain malignant (CNHC-UMF) and
benign features (CNHC-BF) (Figure 1A-F).
CNHC occurring as cellular aggregates (clusters) were
classified as CNHC-MF (Figure 1A) if at least four of the
following criteria were present:
○ Anisonucleosis (ratio >0.5)
○ Nuclei larger than 3 times the calibrated 8 μm pore
size of the membrane
○ Irregular nuclear outline
○ Presence of tridimensional cellular sheets
○ High nuclear/cytoplasmic ratio
Figure 1 Immunocytochemical analysis of CNHCs with antibodies against the hematological marker CD45. Cellular aggregates (clusters)
of non-hematological cells (CNHC) isolated from blood of patients with renal tumors by ScreenCell® filtration (A-C) with cytomorphological
features of malignant (CNHC-MF) (A), uncertain malignant (CNHC-UMF) (B), and benign cells (CNHC-BF) (C) as previously defined [17]. None of
the CNHC are detected by CD45 antibodies, whereas single lymphocytes are CD45-positive (indicated by arrows in A and C). Examples of filter
pores (8 μm in diameter) are marked by arrow heads (B). Single CNHC isolated by ScreenCell® filtration (D-F) with cytomorphological features of
malignant (−MF) (D), uncertain malignant (−UMF) (E), and benign cells (−BF) (F) are CD45-negative. However, leucocytes are stained with CD45
antibodies (arrows in D and F).
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than 4 of these criteria were seen (Figure 1B), whereas
CNHC-BF did not show any of these characteristics
(Figure 1C).
Single CNHC (Figure 1D-F) were classified as CNHC-
MF (Figure 1D) if all 3 of the following cytological criteria
were present:
○ Nuclei larger than 3 times the calibrated 8 μm pore
size
○ Irregular nuclear outline
○ High nuclear/cytoplasmic ratio
If less than 3 of these criteria were present, the sin-
gle cell was CNHC-UMF (Figure 1E). CNHC-BF cells
showed none of the cellular features described above
(Figure 1F). The number of cells was assessed by
counting nuclei of single CNHCs and within CNHC
clusters. The total numbers of CNHCs are listed in
Table 2.Immunocytochemical characterization of filtered cells
After filtration the filters were dissembled from the de-
vice, air-dried over night at room temperature (RT)
and then fixed in 4% m/V formaldehyde (Labonord,
Templemars, France) for 10 min. After rehydration in
Tris-buffered saline (TBS) for 10 min, the filters were
incubated in TBS-Triton (TBS containing 0.2% Triton
X-100) (Merck, Darmstadt, Germany) for 5 min. Following
a washing step with TBS, hydrogen peroxidase blocking
solution (Dako, Glostrup, Denmark) was applied for
10 min followed by incubation with Ultra V Block (Dako,
Glostrup, Denmark) at RT for 5 min. To circumvent the
effect of a possible EMT-associated low expression of
epithelial antigens like cytokeratins in CTCs/CTMs
and because renal cell cancers only weakly express epi-
thelial cell adhesion molecule (EpCAM) [26], carbonic
anhydrase IX (CAIX) was used as a marker. This pro-
tein is overexpressed in 100% of clear cell renal cell
carcinomas and 57% of papillary renal cell carcinomas
[27] but is not expressed in normal renal tissue [28].
Table 2 Summary of the results of cytomorphological classification of CNHCs detected by ScreenCell® filtration in 8 ml
of venous blood of patients with benign (n = 10), malignant (n = 30) renal tumors and healthy controls (n = 20)
Number of CNHC / 8 ml
Clinical data Time point A* Time point B** Time point C*** Time point D****
Patient
number
Histological
diagnosis
TNM Grade Venous
invasion
MF UMF BF MF UMF BF MF UMF BF MF UMF BF
26 angiomyolipoma - - no 0 2 0 0 0 0 0 0 0 0 0 0
33 angiomyolipoma - - no 0 0 0 0 0 0 0 0 0 0 0 0
29 benign cyst - - - 0 0 0 0 10 0 0 0 30 2 0 0
18 cyst. nephroma - - - 51 4 0 2 0 0 0 127 30 30 380 0
3 oncocytoma - - no 0 560 2 0 0 0 0 0 0 0 251 195
4 oncocytoma - - no 0 0 0 0 2 0 0 40 8 0 2 3
6 oncocytoma - - no 0 3 0 0 0 0 2 35 35 0 19 11
14 oncocytoma - - no 0 0 0 0 39 0 37 8 0 21 5 0
17 oncocytoma - - no 2 136 0 0 0 0 1 0 0 2 0 35
38 oncocytoma - - no 0 0 4 0 0 0 0 0 0 0 0 0
1 ccRCC T2aN0M0 2 yes 0 0 0 0 0 0 ND ND ND ND ND ND
2 ccRCC T3aN0M0 2 yes 0 0 0 0 0 3 0 10 0 0 0 0
7 ccRCC T2aN0M0 2 no 0 0 0 0 0 0 0 6 0 ND ND ND
9 ccRCC T1bN0M0 2 no 3 19 5 0 0 0 ND ND ND 0 0 0
10 ccRCC T1N0M0 2 no 16 0 10 0 0 0 0 0 3 0 22 16
11 ccRCC T1N0M0 2 no 0 0 0 2 0 0 ND ND ND 0 0 0
13 ccRCC T3aN0M0 3 yes 0 19 0 0 0 0 22 158 30 ND ND ND
15 ccRCC T1aN0M0 2 no 0 0 0 0 0 0 0 0 0 0 0 0
16 ccRCC T1aN0M0 2 no 62 56 0 0 0 0 0 0 0 0 0 0
19 ccRCC T1aN0M0 1 no 1 0 0 0 0 0 0 0 0 0 3 5
20 ccRCC T3aN0M0 3 yes 13 5 0 0 0 0 20 319 58 ND ND ND
22 ccRCC T1aN0M0 1 no 0 32 0 1 0 0 11 0 0 ND ND ND
23 ccRCC T1aN0M0 1 no 1 0 0 0 1 0 2 0 10 5 12 15
24 ccRCC T1N0M0 1 no ND ND ND 0 0 5 0 1 0 0 0 0
25 ccRCC T1aN0M0 2 no 0 1 0 0 0 0 0 1 20 ND ND ND
28 ccRCC T1bN0M0 1 no 0 0 0 0 645 0 5 5 25 0 36 12
30 ccRCC T1N0M0 3 no 0 0 0 31 227 4 0 0 0 0 67 64
32 ccRCC T1aN0M0 2 no 1 0 0 1 0 0 3 26 15 ND ND ND
34 ccRCC T1aN0M0 2 no 0 0 0 0 26 51 0 18 0 ND ND ND
35 ccRCC T1aN0M0 2 no 0 0 0 0 0 0 ND ND ND 0 20 0
36 ccRCC T1aN0M0 3 no 2 125 3 0 0 0 2 1 7 0 0 0
40 ccRCC T1aN0M0 3 no 0 23 0 0 0 0 0 0 15 0 0 0
41 ccRCC T1aN0M0 3 no 0 0 0 0 0 0 1 0 0 3 74 4
42 ccRCC T1N0M0 1 no 0 0 0 0 0 0 0 22 44 58 124 98
27 pap.RCC T1bN0M0 3 no 0 0 0 0 0 0 0 0 0 1 6 0
8 pap.RCC T1N0M0 2 no ND ND ND 0 0 0 0 0 0 0 0 0
12 pap.RCC T3aN0M0 3 yes 0 0 5 0 0 0 11 0 0 ND ND ND
31 pap.RCC T1aN0M0 2 no 0 0 0 0 0 0 ND ND ND ND ND ND
37 pap.RCC T2aN0M0 2 no 0 0 100 19 79 18 1 0 4 ND ND ND
39 reg RCC T2aN0M0 2 yes 0 0 1 1 0 0 1 0 0 1 0 0
C1 Control - - - 0 0 1 - - - - - - - - -
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Table 2 Summary of the results of cytomorphological classification of CNHCs detected by ScreenCell® filtration in 8 ml
of venous blood of patients with benign (n = 10), malignant (n = 30) renal tumors and healthy controls (n = 20)
(Continued)
C2 Control - - - 0 0 0 - - - - - - - - -
C3 Control - - - 0 2 2 - - - - - - - - -
C4 Control - - - 0 83 100 - - - - - - - - -
C5 Control - - - 0 0 0 - - - - - - - - -
C6 Control - - - 0 0 0 - - - - - - - - -
C7 Control - - - 0 0 12 - - - - - - - - -
C8 Control - - - 0 0 0 - - - - - - - - -
C9 Control - - - 0 1 0 - - - - - - - - -
C10 Control - - - 0 0 0 - - - - - - - - -
C11 Control - - - 0 1 1 - - - - - - - - -
C12 Control - - - 0 0 0 - - - - - - - - -
C13 Control - - - 0 1 2 - - - - - - - - -
C14 Control - - - 0 0 0 - - - - - - - - -
C15 Control - - - 0 0 0 - - - - - - - - -
C16 Control - - - 0 27 5 - - - - - - - - -
C17 Control - - - 0 1 7 - - - - - - - - -
C18 Control - - - 0 0 0 - - - - - - - - -
C19 Control - - - 0 0 0 - - - - - - - - -
C20 Control - - - 0 1 0 - - - - - - - - -
* One day before surgery.
** During surgery, after the removal of the tumor.
*** One day after surgery.
**** Eight days after surgery.
ND Not done (sample not available).
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rected against CAIX (rabbit IgG, NB100-417, Novus
Biologicals, Littleton, USA; 3.5 μg/ml ), CD31 (mouse
IgG1, M0823, Dako, Glostrup, Denmark; 1 μg/ml) or
CD45 (mouse IgG1, M0855, Dako, Glostrup, Denmark;
2.4 μg/ml) diluted in Antibody Diluent (Dako, Glostrup,
Denmark) for 30 min at RT followed by application of pri-
mary antibody enhancer (Dako, Glostrup, Denmark) for
15 min. Thereafter the filters were incubated with labelled
polymer-HRP Anti-Mouse + Anti-Rabbit (Dako, Glostrup,
Denmark) for 10 min. AEC substrate chromogen (Dako,
Glostrup, Denmark) was applied for 10 min and rinsed off
with distilled water prior to counterstaining with hematoxylin
(Merck, Darmstadt, Germany) as described above. Respective
non-immune rabbit IgG and isotype-matched monoclonal
antibodies were used as controls. Cultured 769-P and HIAEC
cells were spiked in blood, filtered and stained like patient
samples and served as positive or negative control for stain-
ing, enumeration and array-CGH experiments.
Laser capture microdissection and whole genome
amplification of selected filtered cells
Isolation of selected CNHCs was carried out by laser cap-
ture microdissection (P.A.L.M., Zeiss, Munich, Germany).Before laser capture microdissection, all non-target
cells and cellular debris were removed by laser abla-
tion. The polycarbonate filter was then cut with a
pulsed laser beam and the membrane and target cells
were catapulted into the lid of a 200 μl PCR tube,
which contained 10 μl of WGA-4 fragmentation and
lysis buffer (#WGA4, Sigma-Aldrich, St. Louis, USA)
(Figure 2). An exemplary laser capturing is shown in
Additional file 1: Movie 1. For control purposes neu-
trophilic granulocytes, which were subjected to the
same filtration and staining procedures like patient
samples, were as well isolated by laser capture micro-
dissection and forwarded to whole genome amplifica-
tion (WGA). WGA was performed as previously described
[29] with minor modifications using the GenomePlex Sin-
gle Cell Whole Genome Amplification Kit (Sigma-Aldrich,
St. Louis, USA). Briefly, the captured cells were digested in
10 μl fragmentation and lysis buffer, followed by
GenomePlex library preparation. Amplification was
performed by adding 7.5 μl of 10× amplification master
mix, 48.5 μl nuclease free water and 5 μl WGA DNA poly-
merase. After whole genome amplification, DNA was
purified using the GenElute PCR Clean-Up Kit (Sigma-
Aldrich, St. Louis, USA). DNA concentration and purity
Figure 2 Laser capture microdissection of a CNHC cluster. Filter membrane with a single CNHC (arrow head) and a CNHC cluster (arrow) (A).
The single CNHC was removed by laser ablation before the membrane surrounding the cluster was cut by laser beam. The membrane and CNHC
cluster was then laser pressure catapulted into the lid of a reaction tube (B-C).
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Fisher Scientific, Waltham, USA). DNA quality was assessed
by multiplex PCR as previously described [25]. Samples
showing three to four DNA bands between 100 and 400 bp
were regarded as of high DNA quality.
Array-CGH
Array-CGH was performed using SurePrint G3 Human
CGH Microarrays 8×60K (Agilent Technologies, Santa
Clara, USA). Prior to labelling, genomic DNA derived
from snap frozen and FFPE tissues as well as the corre-
sponding reference DNA were digested by Alu I and Rsa
I (Promega, Fitchburg, USA) according to the supplier’s
instructions. Amplified DNA of CNHCs and the corre-
sponding amplified reference DNA (Promega, Fitchburg,
USA) showed mean DNA size distributions of 400 -
600 bp and therefore provided suitable templates for
array-CGH without any digestion step. The purified
samples were labelled with the Bioprime Array CGH
Genomic Labeling System (Life Technologies, Carlsbad,
USA). Briefly, 250 ng of sample DNA and 250 ng of fe-
male or male reference DNA (Promega, Fitchburg,
USA) were labelled with dCTP-Cy5 and dCTP-Cy3
(GE Healthcare, Little Chalfont, UK), respectively. Sub-
sequently, DNA was purified with Amicon Ultracel-30
filters (Millipore, Billerica, USA) and mixed in equal
amounts. The mixture was hybridized to a 60 K array ON
using the Oligo aCGH/ChIP-on-chip Hybridization kit
(Agilent Technologies, Santa Clara, USA). Following
hybridization, the array was washed and scanned (Agilent
Technologies, Santa Clara, USA) as recommended by the
manufacturer. Data analysis was performed with Agilent
Genomic Workbench Lite Edition 6.5.0.18. (Agilent
Technologies, Santa Clara, USA). The following set-
tings were used for tumor tissues: ADM-2, threshold
8.0, with at least 10 consecutive oligos with an absolutelog ratio of 0.22. For amplified DNA the algorithm
ADM-2, threshold 9.3 was used with at least 100 con-
secutive oligos with an absolute log ratio of 0.30.
Definition of thresholds and controls for array-CGH
As it was our purpose to characterize CNHC clusters,
pools of leucocytes and 769-P cells were used to test the
detection limits of genetic aberrations of the array-CGH
method. 769-P cells and leucocytes were subjected to
ScreenCell® filtration, microdissected from the filters, the
DNA was subjected to WGA and further analysed by
array-CGH. There was concordance of gains and losses
of chromosomal DNA detected in amplified pools of ten
769-P cells and non-amplified DNA from cultured 769-P
cells [30] (Figure 3). From this comparison we estimated
that deletions of approximately ~6.8 Mb can be detected
in pools of ten 769-P cells (chromosome 9, genomic pos-
ition 16.2-23.0 Mb) which is sufficient to indicate larger
scale aberrations in RCC [31]. The DNA of isolated
pools of 10 leucocytes from blood of a healthy individ-
ual, representing a balanced genome, was used to set the
thresholds for the detection limits of gains and losses by
array-CGH in our study. In contrast to cell cultured cells,
the array-CGH profiles of amplified DNA of CNHCs
demonstrated slightly noisier ratio profiles, as we expected
if going from an artificial cell culture system to clinical
samples. By applying the above mentioned threshold
settings, gains and losses could be reliably detected
(Figure 3).
Statistical analysis
We investigated if the presence or absence of CNHC
types (categorized as binary variables) differed between
time points A–D, using Chi-square tests. Furthermore,
median, minimum and maximum were used to describe
the number of CNHCs of each type and for every time
Figure 3 Control array-CGH profiles of the renal cancer cell line 769-P. DNA of the non-amplified 769-P cell line reveals gains of
chromosomes 1q, 5q, 8q and losses of 1p, 3p, 6, 9p, 11q, 14 (A, red profile). The corresponding array-CGH profiles of amplified DNA of two
biological replicates (ten 769-P cells each) show concordant gains of 1q, 8q, losses of 1p, 3p, 9p, 11q, 14 (B, blue and green profile, respectively).
In one of the 769-P cell pools there was an additional loss of 15q (B, blue profile). Gains and losses of the X- and Y-chromosomes (blue profile in
B) do not reflect true copy number variations. They result from differences between the sex of the reference and the samples DNA (e.g. female
sample DNA was hybridized against a male reference DNA thereby resulting in a gain of X and loss of Y chromosome).
Figure 4 Overall frequencies of the CNHC types in healthy
controls and patients before surgery. Percentage of blood
samples positive for CNHC-MF, -UMF and BF- types. In renal cancer
patients, CNHC of the MF-type were significantly more frequently
detected than in healthy controls (29% vs 0%, p = 0.014).
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each type with tumor size, venous invasion and differenti-
ation grade were explored using nonparametric methods.
A p-value of <0.05 was considered to indicate statistical
significance. All p-values were regarded in an explorative
sense. The statistical calculations were performed using the
SPSS software package, version 20.0 (IBM, Armonk, USA).
Results
Spiking experiments
The average number of recovered 769-P cells for 50, 10
and 2 spiked cells were 45.3 (SD 2.1), 8.7 (SD 1.5), and
1.7 (SD 0.6), respectively. The average recovery rates of
769-P were 91%, 87% and 83% for 50, 10 and 2 spiked
769-P cells, respectively which compares to sensitivity
rates published by Desitter et al. for the ScreenCell® fil-
tration device [15].
Cytomorphological analysis of CNHC types in patients
with renal tumors and healthy controls
Overall CNHCs of the MF-type were detected more fre-
quently in renal cancer patients (29%) as compared to
healthy controls (0%) (p = 0.014). CNHC-MF were also
found in 20% of cases with benign renal tumors which
was not significantly different from the frequency found
in healthy controls (p = 0.103). However in healthy con-
trols CNHC-MF were not found. CNHC-UMF and –BF
types were identified in the blood of 29% and 21% of the
renal cancer patients, in 50% and 20% of benign renal
tumor patients as well as in 40% and 40% of healthy in-
dividuals (Figure 4).
A summary of the results of the cytomorphological
analyses and the number of cells of all patients and time
points is provided in Table 2.Overall, one day before surgery (time point A) 26%,
34%, and 21% of the blood samples were positive for
CNHC-MF, -UMF and –BF, respectively. However, dur-
ing surgery, after removal of the renal tumor (time point
B) CNHC-MF, -UMF and -BF were found in only 18%,
20% and 13% of samples, respectively. One day after sur-
gery (time point C) there was a significant increase in
the number of blood samples positive for CNHC-MF
(40%, p = 0.040), -UMF (43%, p = 0.045) and BF (43%,
0.004). Eight days after surgery (time point D) 48% of
the samples were positive for CNHC-UMF and 38%
were positive for CNHC-BF, whereas in only 31% of
samples CNHC-MF were found (Figure 5).
Figure 5 Percentage of patient samples positive for CNHC-MF, -UMF
and BF at different time points of sampling. Percentage of
blood samples positive for CNHC-MF (circle), CNHC-UMF (rectangle), and
CNHC-BF (triangle) one day before surgery (time point A), during surgery,
after the removal of the tumor (time point B), one day after surgery (time
point C), and 8 days after surgery (time point D). There was no significant
change in the percentage of blood samples positive for CNHC of any type
after surgery (time points C and D, respectively) as compared to before
surgery (time point A). However, a significant increase of samples positive
for CNHCs of every type was found at time point C as compared to time
point B (p < 0.05, each). Blood samples positive for CNHC-UMF and CNHC-
BF but not CNHC-MF, were also more frequently detected at time point D
as compared to time point B.
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either as single cells or clusters were found at every time
point in patients regardless of the histological tumor diag-
nosis (Table 2).
The median number of CNHC-MF per 8 ml of blood
was 3 cells (range: 1–62) before surgery (time point A),
2 cells (range: 1–31) during the surgery (time point B), 3
cells (range: 1–37) one day after surgery (time point C)
as well as 3 cells (range: 1–58) eight days after surgery
(time point D) (Figure 6A). The median number of
CNHC-UMF per 8 ml of blood was 19 cells (range: 1–560)
at time point A, 33 cells/8 ml (range: 1–645) at time
point B, 18 cells/8 ml (range: 1–319) at time point C
and 21 cells/8 ml (range 2–380) at time point D (Figure 6B).Figure 6 Numbers of CNHC-types at different time points. Numbers o
time points A-D. Median cell numbers are given for each time point.Cells with benign features represented with a median num-
ber of 4 cells/8 ml (range: 1–100) at time point A, 5 cells/
8 ml (range: 3–51) at time point B, 20 cells/8 ml (range:
3–58) at time point C and 15 cells/8 ml (range: 3–195) at
time point D (Figure 6C). In renal cancer patients there
was no correlation between histopathological tumor pa-
rameters (tumor size, grade of differentiation) and detec-
tion of CNHC regardless of type or time point examined
(Additional file 2: Table S1 and Additional file 3: Table
S2). However, one day after surgery (time point C) higher
numbers of CNHC-MF were detected in patients with
RCC with venous invasion as compared to those cases
without venous invasion (p = 0.013). This was not found
at any of the other time points investigated (Additional file 4:
Table S3).
In the blood of healthy controls no CNHC-MF were
detected. In three out of 20 cases (15%) we found CNHC
clusters, primarily of the BF- (14 clusters) and UMF-
types (6 clusters). In 7 out of 20 cases (35%) we found
single CNHCs, mostly of the BF- (13 cells) and less fre-
quently the UMF-types (5 cells). Overall, 0%, 40%, and
40% of the blood samples from healthy controls were
positive for CNHC-MF, -UMF and -BF, respectively
(Table 2). All detected CNHCs were negative for CAIX
or CD45. However, 4 CNHC clusters of the –BF type
and 2 of the –UMF type were positive for CD31.
Immunocytochemical analysis of CNHC in patients with
renal tumors
Results of the immunocytochemical analyses are com-
piled in Table 3.
On the 53 filters stained with antibodies against CD45
(Figure 1A-F), hematological cells including lymphocytes
and polymorphic nuclear granulocytes showed a positive
staining, whereas the CNHC-MF, -UMF and –BF, either
present as cell clusters (Figure 1A-C) or as single cells
(Figure 1D-F) were without exception negative.
On the 46 filters stained with antibodies against the
RCC marker CAIX (Figure 7), 28 CNHC clusters weref CNHC-MF (A), -UMF (B), and –BF (C) per 8 ml of venous blood at
Table 3 Summary of the immunocytochemical analysis of CNHCs with antibodies against CD45, CD31, and CAIX
Single CNHCs positive with CD45/CAIX/CD31 antibodies CNHC clusters positive with CD45/CAIX/CD31 antibodies
N (%) N (%)
CD45 CAIX CD31 CD45 CAIX CD31
CNHC-MF 0/3 (0%) 5/9 (56%) 0/1 (0%) 0/5 (0%) None detected 3/3 (100%)
CNHC-UMF 0/4 (0%) 0/4 (0%) 1/3 (33%) 0/12 (0%) 1/16 (6%) 17/17 (100%)
CNHC-BF 0/2 (0%) 0/1 (0%) 0/6 (0%) 0/8 (0%) 0/12 (0%) 8/13 (62%)
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nancy, 16 were classified as CNHC-UMF and 12 were
CNHC-BF. Of the 16 CNHC-UMF clusters, one (6%)
was decorated by CAIX antibodies (Figure 7A), 15 (94%)
were negative (Figure 7B), as was the case with the 12
CNHC-BF (Figure 7C). Nine single CNHC-MF were
detected, 5 (56%) of which exhibited positive cytoplas-
mic reactivity (Figure 7D), whereas 4 (44%) were nega-
tive (Figure 7E). Only 4 single CNHC-UMF and one
CNHC-BF were found and these cells were also CAIX-
negative (Figure 7F and 7G, respectively).
Immunocytochemical analysis of 14 filters with anti-
bodies against the endothelial cell marker CD31 (Figure 8)
yielded 3 CNHC-MF- and 17 CNHC-UMF cell clusters,
all of which were CD31 positive (Figure 8A and B, respect-
ively), as were 8 (62%) of the 13 CNHC-BF clusters
(Figure 8C). Of single cells, only one cell with UMF
was CD31 positive.Figure 7 Immunocytochemical analysis of CNHCs with antibodies aga
classified as uncertain malignant (−UMF) with cytoplasmic positive staining
UMF and -BF without reactivity for CAIX antibodies (B and C, respectively).
for CAIX (E). Single CAIX-negative CNHC-UMF and -BF (F and G, respectiveArray-CGH
After WGA, 55 out of 115 (48%) stained microdissected
cells yielded DNA products. According to the multiplex
PCR, the DNA quality of 49% (27 of 55) of these cells
was suitable for array-CGH. Six of CNHC-MF- and 6 of
CNHC-UMF-types were selected for array-CGH ana-
lysis. All passed multiplex quality control and yielded in-
formative array-CGH profiles. The DNA of the CNHC
clusters and the respective renal tumor tissues, one case
of papillary RCC (Figure 9), two cases of clear cell RCC
(Figure 10 and Additional file 5: Figure S1), one oncocytoma
(Figure 10) as well as one cystic nephroma (Additional file 5:
Figure S1) were subjected to array-CGH analysis. The re-
sults are summarized in Table 4.
The chromosomal aberrations found in the DNA of the
tumor tissues are in keeping with the genetic alterations
reported for ccRCC, papRCC, and oncocytoma in the lit-
erature [31-33] and copy number aberration databaseinst the RCC marker CAIX. Clusters of CNHCs cytomorphologically
with antibodies against the RCC marker CAIX (A). Clusters of CNHC-
A single CNHC-MF with positive cytoplasmic (D) and without staining
ly).
Figure 8 Immunocytochemical analysis of CNHCs with antibodies against the endothelial marker CD31. Clusters of CNHC-MF (A), -UMF
(B), and -BF (C), with cytoplasmic staining for CD31.
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nign renal cyst of one patient (patient # 18) was of in-
sufficient quality for analysis by array-CGH. Irrespective of
the cytomorphological type, most of the CNHC clusters
showed a balanced genome. In only two of the 12 (17%)
CNHC clusters, one of which was a MF- and the other
one was a UMF- cytomorphological type chromosomal
aberrations could be identified which did not match the
patterns of chromosomal changes found in the respective
renal tumors (Table 4).
Discussion
We evaluated the feasibility and utility of the ScreenCell®
filtration system for the detection of CTCs and CTMs in
the blood of patients with RCC. We investigated if mor-
phological features can be used to discriminate between
malignant and non-malignant cells by applying array-CGH.
We found the ScreenCell® filtration an easy to perform
procedure which allowed for the detection of large cells
(i.e. diameter of > 8 μm) after filtration of 8 ml of diluted
blood in 60% of patients with benign and in 53% with
malignant renal tumors one day before surgical interven-
tion. According to their cytomorphological features,
these cells either occurring as single cells or cellular
clusters consisting of at least 3 cells were classified as
CNHC-MF, -UMF or -BF using diagnostic criteria re-
cently published by a panel of expert cytopathologists
[17]. Surprisingly, each type of CNHCs was found in
blood of patients with benign renal tumors including renal
cysts, cystic nephroma, angiomyolipomas, oncocytomas as
well as malignant papillary or clear cell RCCs. The pres-
ence of CNHCs did not correlate with histopathological
features of the respective tumors including tumor size,
histological diagnosis and grade of tumor differentiation.
However, in patients with renal cancer a correlation be-
tween the CNHC-MF numbers and histological venous
invasion was found at time point C (one day aftersurgery). At time point A (one day before surgery)
CNHC-MF were also more frequently detected in renal
cancer patients as compared to healthy controls.
Immunocytochemical analysis revealed that single cells
or cellular clusters found on the filters could be regarded
as CNHCs because they were invariably negative for
CD45, an established marker for hematological cells
[35]. Indeed, the results of the CD31 immunocytochem-
ical staining and genetic analysis seem to indicate that
most of the cellular CNHC clusters identified in our
study may represent aggregations of circulating endothe-
lial cells (CECs) rather than CTMs. More than half
(62%) of the clusters of CNHCs-BF-type and all of the
CNHC of the -MF and -UMF types found on the filters
analysed with antibodies against CD31 were positive,
whereas only 6% of the CNHC-UMF- and none of the
CNHC-BF clusters were positive on the filters stained
for the RCC marker CAIX [36,37]. Although with lower
staining intensity as compared to endothelial cells, neutro-
philic granulocytes, some lymphocytes, monocytes and
platelets can also be stained by the CD31 antibodies [38].
Therefore we cannot exclude that the CNHC clusters may
contain some of these cell types as well. However, this is
not supported by their cytomorphological features and
negative staining results with CD45-antibodies.
In contrast to what was observed for the CNHC clus-
ters, 56% of the single CNHC-MF on the filters analysed
with antibodies against the renal cancer marker CAIX
[36,37] were positive and might thus represent “true”
CTCs. Only 1 out of 10 single CNHC (10%) was positive
for CD31. Unfortunately, only DNA of insufficient qual-
ity could be generated from single CNHCs of any type
precluding array-CGH characterisation of these cells.
Analysis of limited amounts of DNA, as in the analysis
of CTCs is faced with several technical problems. Proce-
dures of fixation and staining can decrease DNA quality
and interfere with the whole genome amplification (WGA)
Figure 9 Array-CGH profiles of the DNA of a papillary RCC and the respective CNHCs. The DNA of the papillary RCC of patient #37 shows
gains at chromosomes 6p, 7, 16, 17q, 20 and loss of chromosome Y, changes typically found in pap. RCC (red profile). However, the array-CGH
profiles of three CNHC-MF clusters (photographs A-C) are balanced (profiles A-C), whereas losses at chromosomes 3p and 4q are identified in the
DNA of a CNHC-UMF cluster (photograph D and profile D, respectively) isolated from the same patient. The two clusters shown in photograph A
and D are negative for CD45. All other clusters were hematoxylin stained. As a control, the DNA of an isolated pool of 10 leucocytes from blood
of a healthy individual showed a balanced genome (leucocyte control). Gains and losses of the X- and Y-chromosomes (profile B and leucocyte
control) do not reflect true copy number variations. They result from differences between the sex of the reference and the samples DNA
(i.e. male patient DNA was hybridized against a female reference DNA thereby resulting in a loss of X and gain of Y chromosome). Bars above the
x-axis are considered to be gains, below the x-axis losses of DNA.
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ate sufficient quantities of DNA for array-CGH, all of
which are prone to amplification bias [40-42]. We there-
fore used the GenomePlex library technology which has
been shown to exhibit no nucleotide related amplification
bias [43,44]. In addition, the reference DNA was also amp-
lified using GenomePlex library technology to further
minimize the amplification bias [45]. Array-CGH profiles
from amplified DNA of few cells tend to be “noisier” than
compared to non-amplified DNA [39,43]. Although higher
resolutions are reported with dense array platforms [43],copy number variations as small as 6.8 Mb could be identi-
fied in our study which seems appropriate to detect large
scale aberrations described in RCC [31].
CTMs have been described in several CTC isolation
procedures [19,46,47], in particular with techniques rely-
ing on size filtration [11,17,20]. Based on their cytological
features some were designated “atypical”, “uncertain ma-
lignant” or “morphologically doubtful” [17,48,49]. How-
ever, endothelial cells, megakaryocytes as well as large
monocytes may be difficult to distinguish from “true”
CTC or CTM [17]. The reason why circulating benign
Figure 10 Array-CGH profiles of the DNA of an oncocytoma or clear cell RCC and the respective CNHCs. The DNA of the oncocytoma
represents with typical losses at chromosomes 1, 14, 17, 22 and Y (red profile). Array-CGH profile of the DNA of a CNHC-MF cluster (photograph
A) reveals a gain of 1p and loss of chromosome 9 (profile A), whereas the profiles of another CNHC-MF cluster (photograph B) and a CNHC-UMF
cluster (photograph C) indicated no detectable copy number variations (profiles B and C, respectively). The DNA of the clear cell RCC of patient
#16 reveals gains of 1p, 2p, 5q, 17 and a loss of 3p (green profile) commonly observed in clear cell RCC. The array-CGH profile of the DNA of a
CNHC-MF (photograph D) of patient #16 is balanced (profile D). All clusters were hematoxylin stained. As a control, the DNA of an isolated pool
of 10 leucocytes from blood of a healthy individual showed a balanced genome (leucocyte control). Gains and losses of the X- and Y-
chromosomes (green profile, profile A and D) do not reflect true copy number variations. They result from differences between the sex of the
reference and the samples DNA (i.e. male patient DNA was hybridized against a female reference DNA thereby resulting in a loss of X and gain of
Y chromosome). Bars above the x-axis are considered to be gains, below the x-axis losses of DNA.
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changes might be introduced by shear forces in circulation
and/or during filtration.
In some studies the ScreenCell® filtration technique
was applied to isolate CTC/CTM from the blood of pa-
tients with adrenocortical, prostate, colon and breastcancer or malignant melanoma [15,50,51]. These cells
have been characterized by immunocytochemistry or
telomeric analysis. However, array-CGH data or results
from immunocytochemical testing with CD31 antibodies
have not been reported. Here we describe for the first time
array-CGH analysis of CNHC clusters cytomorphologically
Table 4 Summary of the results of array-CGH profiling of
the DNA of primary tumors and respective CNHCs
Chromosomal aberrations
identified by array-CGH
Patient
number
Items analysed
by array-CGH
Gains Losses
14 Oncocytoma None detected 1, 14, 17, 22, Y
CNHC-MF (A) 1p 9
CNHC-MF (B) Balanced Balanced
CNHF-UMF (C) Balanced Balanced
16 Clear cell RCC 1p, 2p, 5q, 17 3p
CNHC-MF (D) Balanced Balanced
18 Cystic nephroma Not analysed* Not analysed*
CNHC-UMF (C)** Balanced Balanced
CNHC-UMF (D)** Balanced Balanced
30 Clear cell RCC** 5q, 7 3p
CNHC-UMF (A)** Balanced Balanced
CNHC-UMF (B)** Balanced Balanced
37 Papillary RCC 6p, 7, 16, 17q, 20 Y
CNHC-MF (A) Balanced Balanced
CNHC-MF (B) Balanced Balanced
CNHC-MF (C) Balanced Balanced
CNHC-UMF (D) None detected 3p, 4q
* Unfortunately the quality of the DNA generated from the tumor tissue was
not suitable for array-CGH due to insufficient quality.
** Array-CGH profiles are available as additional information (Additional file 5:
Figure S1).
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majority of the clusters of the CNHC-MF as well as the
CNHC-UMF types did not show chromosomal aberrations
and had a balanced genome. The DNA of one CNHC-
UMF cluster isolated from a patient with pap. RCC and
one CNHC-MF cluster from a patient with oncocytoma
showed distinct chromosomal abnormalities on array-
CGH which, however, did not match the aberrations found
in the respective primary tumors (Figures 9 and 10, re-
spectively) nor in a copy number aberration database
(www.progenetix.net) [34]. It might be speculated that
these CNHC clusters represent true CTMs. The reason for
the differences of the chromosomal aberrations in the
CNHCs and the respective tumors is not known, however,
tumor heterogeneity [52] might be one of the factors
responsible.
Data from animal models and patients with non-
small-cell lung cancer indicate that cellular aggregates
in blood may consist of CTCs associated with non-
neoplastic cells like stromal cells which could enhance
CTC survival and the metastatic process [23,53]. It has
been estimated that array-CGH can detect gains and losses
in mixed populations of tumor and non-neoplastic cells,
if more than 20-25% of the population consist of tumorcells [54,55]. Therefore we cannot exclude that the CNHC
of -MF or -UMF types without chromosomal aberrations
described in our study also contain low numbers of CTCs
that were not detectable by array-CGH.
Our results indicate that CNHC can be isolated from
blood of patients with renal tumors using the ScreenCell®
system. The majority of the isolated clusters may be of
endothelial origin as indicated by positive staining with
CD31 antibodies. These putative endothelial cell aggre-
gates have hitherto not been reported in patients with
renal tumors. It might be speculated that they mirror ac-
tive angiogenesis in the tumors or during wound healing
after surgery [56]. Increased numbers of CECs, probably
shed from activated or damaged tumor vessel walls
[57,58] and circulating endothelial progenitor cells derived
from the bone marrow have been described in the blood
of cancer patients and may importantly contribute to can-
cer growth and metastasis (reviewed in [58-60]). CECs are
also found in several other clinical syndromes with vascu-
lar injury as well as in response to chemotherapy and anti-
angiogenic treatment [61,62]. Therefore CECs and/or
endothelial progenitor cells are considered biomarkers of
vascular damage. Recently published data suggest CECs as
prognostic [63] as well as predictive markers for response
to anti-angiogenic therapy in prostate [64] and metastatic
renal cell cancer [65-67]. However, their application as
biomarkers in clinical practice has been limited by the dif-
ficulty to reliably detect them by flow cytometry [68]. Al-
though limited by the relatively small number of cases
analysed, the results of our study might indicate that de-
tection of CECs may be facilitated by filtration based and
immunocytochemical augmented methods. In this respect
it is interesting that we detected a significant increase of
the percentage of blood samples positive for all types of
CNHCs one day after surgery as compared during surgery.
This was also found for CNHC-UMF and –BF-positive
samples, but not CNHC-MF-containing samples eight
days after surgery.Conclusions
For patients with renal tumors cytomorphological classi-
fication alone seems not to be sufficient to allow for reli-
able distinction of epithelial CNHCs - the putative CTCs
or CTMs - from endothelial CNHCs. As also suggested
by others, reliable detection of CTCs or CTMs should
thus be confirmed by immunocytochemical and/or mo-
lecular biological methods [17,69].Additional files
Additional file 1: Movie 1. An exemplary laser capture microdissection.
Additional file 2: Table S1. Correlation of tumor size and number of
CNHCs.
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of CNHCs.
Additional file 4: Table S3. Relationship of venous invasion and
number of CNHCs.
Additional file 5: Figure S1. Array-CGH profiles of the DNA of a clear
cell RCC and the respective CNHCs or CNHCs derived from a patient with
a cystic nephroma. The DNA of the clear cell RCC of patient #30 reveals
gains of 5q, 7 and losses of 3p, changes commonly observed in clear cell
RCC (red profile). The array-CGH profile of the DNA of two CNHC-UMF
clusters (photograph A and B) of patient #30 represent with balanced
genomes (profile A and B). The array-CGH profile of the two CNHC-UMF
clusters (photograph C and D) revealed balanced genomes (profile C and
D). All clusters were hematoxylin stained. The DNA of the respective renal
tissue was not suited for array-CGH analysis due to insufficient quality.
Gains and losses of the X- and Y-chromosomes do not reflect true copy
number variations. They result from differences between the sex of the
reference and the samples DNA (i.e. male patient DNA was hybridized
against a female reference DNA thereby resulting in a loss of X and gain
of Y chromosome and vice versa). Bars above the x-axis are considered to
be gains, below the x-axis losses of DNA.
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